BPTF-Related Neurodevelopmental Disorder: Comprehensive Disease-Characteristics Report

Executive summary and evidence limits

BPTF-related neurodevelopmental disorder is a rare Mendelian chromatin-remodeling disorder, conventionally named neurodevelopmental disorder with dysmorphic facies and distal limb anomalies (NEDDFL). It results primarily from heterozygous loss-of-function variants in BPTF and is best understood as an autosomal-dominant haploinsufficiency disorder. Developmental/intellectual disability, speech-language delay, postnatal microcephaly, and recognizable but variable dysmorphism form the core phenotype; motor delay, hypotonia, growth impairment, seizures, mild brain abnormalities, ophthalmologic findings, scoliosis, and distal-limb anomalies broaden the spectrum. The evidence base remains small: the landmark 2017 study described ten unrelated individuals, and the major 2021 expansion reported approximately 25–26 affected individuals with 20 distinct variants. Consequently, frequencies below are cohort proportions—not population estimates—and are vulnerable to referral and ascertainment bias. (glinton2021phenotypicexpansionof pages 1-3, stankiewicz2017haploinsufficiencyofthe pages 1-2, glinton2021phenotypicexpansionof pages 3-4)

Recent disease-specific literature is sparse. Important 2023 and 2024 reports concern growth-hormone use and epilepsy, respectively, but their full text was unavailable in the retrieved corpus; they are therefore flagged without extrapolating outcomes. No disease-specific interventional trial was identified. The strongest mechanistic development is the 2022 forebrain-specific mouse model and its RNA-sequencing analysis. (zapata2022generationofa pages 1-2)

1. Disease information

Definition and nomenclature

Preferred name: BPTF-related neurodevelopmental disorder.
Established alternative name: neurodevelopmental disorder with dysmorphic facies and distal limb anomalies.
Abbreviation: NEDDFL.
Category: Mendelian, syndromic neurodevelopmental disorder/chromatinopathy.

The 2021 abstract defines NEDDFL as being “defined primarily by developmental delay/intellectual disability, speech delay, postnatal microcephaly, and dysmorphic features” and resulting from heterozygous variants in dosage-sensitive BPTF. (glinton2021phenotypicexpansionof pages 1-3)

Identifiers

• OMIM phenotype: 617755, NEDDFL.
• Gene/locus: BPTF, chromosome 17q24.2.
• MONDO: a disease-specific MONDO accession could not be verified from the retrieved primary literature; do not assign one without direct MONDO lookup.
• Orphanet: no disease-specific Orpha code was verified.
• ICD-10/ICD-11 and MeSH: no specific code/descriptor was identified. Coding generally requires broader categories for developmental/intellectual disability, microcephaly, epilepsy, or congenital malformations.

The source data are aggregated disease-level data from published case series and experimental studies, not an EHR-derived natural-history cohort. Individual-patient observations underlie the aggregate proportions. (stankiewicz2017haploinsufficiencyofthe pages 1-2, glinton2021phenotypicexpansionof pages 3-4)

2. Etiology

Causal factor

The primary cause is a heterozygous germline pathogenic variant or deletion affecting BPTF. The leading mechanism is reduced dosage—haploinsufficiency—rather than infection, toxin exposure, autoimmunity, or a metabolic enzyme defect. The 2017 cohort contained eight loss-of-function and two missense variants; the expanded cohort was dominated by frameshift, nonsense, splice, and exon-level loss variants. (glinton2021phenotypicexpansionof pages 3-4, stankiewicz2017haploinsufficiencyofthe pages 1-2)

Genetic risk

A pathogenic BPTF allele is itself the principal risk factor. Most initially reported variants were de novo, but the 2021 study documented four inherited changes, including transmission from non-mosaic affected parents, demonstrating vertical autosomal-dominant transmission and variable expressivity. (glinton2021phenotypicexpansionof pages 3-4)

No validated modifier gene, susceptibility locus, protective allele, founder mutation, ancestry enrichment, or carrier-frequency estimate is established. Missense and some inherited variants have been associated with milder presentations, but this is not yet a validated genotype–phenotype rule. (glinton2021phenotypicexpansionof pages 12-13, glinton2021phenotypicexpansionof pages 3-4)

Environmental and protective factors

No causal environmental, occupational, lifestyle, dietary, or infectious exposure has been demonstrated. No genetic or environmental protective factor has been reported. There is likewise no disease-specific gene–environment interaction literature. These are evidence gaps, not evidence that environmental influences can never affect clinical functioning.

3. Phenotypes

The most reproducible phenotype data are summarized below. Differences between quoted frequencies reflect different denominators, missing data, and whether the calculation concerned the novel cohort or all available individuals.

Neurodevelopmental and neurologic features

• Developmental delay/intellectual disability: 10/10 in the 2017 cohort and approximately 88% in the 2021 expanded cohort. Severity is variable; onset is infancy/childhood and impairment is generally chronic. Suggested terms: HP:0001263 Global developmental delay, HP:0001249 Intellectual disability. (stankiewicz2017haploinsufficiencyofthe pages 1-2, glinton2021phenotypicexpansionof pages 3-4)
• Speech-language delay: 10/10 in 2017 and approximately 85% in 2021. This is among the most consistent, functionally important manifestations. Suggested term: HP:0000750 Delayed speech and language development. (stankiewicz2017haploinsufficiencyofthe pages 1-2, glinton2021phenotypicexpansionof pages 3-4)
• Motor delay: approximately 69% in the expanded cohort. Suggested term: HP:0001270 Motor delay. (glinton2021phenotypicexpansionof pages 3-4)
• Hypotonia: history in approximately 38%. Suggested term: HP:0001252 Hypotonia. (glinton2021phenotypicexpansionof pages 4-5)
• Microcephaly: postnatal microcephaly occurred in 7/9 in 2017. The expanded-study extractions report 42% in one denominator and 60% at assessment in another, while 40% had microcephaly at birth. The safest conclusion is that microcephaly is common but neither universal nor always strictly postnatal. Suggested terms: HP:0000252 Microcephaly and, only where serial measurements document it, HP:0000253 Progressive microcephaly. (stankiewicz2017haploinsufficiencyofthe pages 1-2, glinton2021phenotypicexpansionof pages 4-5)
• Seizures/EEG abnormalities: six expanded-cohort participants had a seizure history requiring treatment; two additional individuals had electrographic abnormalities without reported clinical seizures. Suggested terms: HP:0001250 Seizure, HP:0010843 Abnormality of the EEG. (glinton2021phenotypicexpansionof pages 4-5)
• Brain MRI: among 13 imaged individuals, 8 MRIs were normal and 5 showed mild structural abnormalities. Thus, a normal MRI does not exclude the disorder. Suggested term: HP:0410263 Abnormal brain MRI when applicable. (glinton2021phenotypicexpansionof pages 4-5)

Growth, craniofacial, skeletal, and ocular features

• Short stature: approximately 25%; decreased weight/poor weight gain: approximately 53%. Suggested terms: HP:0004322 Short stature, HP:0004325 Decreased body weight/Poor weight gain, with exact HPO chosen to match the measured phenotype. (glinton2021phenotypicexpansionof pages 4-5)
• Dysmorphism: 9/10 in 2017; 77% in one 2021 aggregate, while all 20 individuals with detailed available dysmorphology data had mild dysmorphism. Recurrent descriptions include a prominent nasal ridge, bulbous nasal tip, and pointed chin. Suggested umbrella term: HP:0001999 Facial dysmorphism, supplemented by feature-specific terms. (stankiewicz2017haploinsufficiencyofthe pages 1-2, glinton2021phenotypicexpansionof pages 4-5, glinton2021phenotypicexpansionof pages 9-10)
• Distal-limb/skeletal abnormalities: cutaneous syndactyly, sandal gap, limb-length discrepancy, delayed bone age, and scoliosis occur variably. Suggested terms include HP:0001159 Syndactyly and HP:0002650 Scoliosis. (glinton2021phenotypicexpansionof pages 9-10, glinton2021phenotypicexpansionof pages 1-3)
• Ophthalmologic complications: reported as an expanded component of the phenotype, but precise frequencies and diagnoses were unavailable in the extracted evidence. Use HP:0000478 Abnormality of the eye only as a parent term pending patient-specific coding. (glinton2021phenotypicexpansionof pages 1-3)

Behavioral, laboratory, and quality-of-life data

No consistent disease-specific psychiatric or behavioral profile, biochemical laboratory signature, validated patient-reported outcome, EQ-5D/SF-36 dataset, or formal quality-of-life study was identified. Nevertheless, cognitive, speech, motor, seizure, and visual impairments predict substantial effects on communication, education, independence, and caregiver burden. That functional interpretation is clinically reasonable but has not been quantified specifically for NEDDFL.

4. Genetic and molecular information

Gene and variant spectrum

BPTF encodes bromodomain PHD finger transcription factor, the largest subunit of the nucleosome-remodeling factor (NURF) complex. In 2017, ten unrelated individuals carried eight loss-of-function and two missense variants; eight variants were confirmed de novo and two had unresolved parental origin. (stankiewicz2017haploinsufficiencyofthe pages 1-2)

The expanded study reported 20 distinct variants: 9 frameshift, 4 nonsense, 3 splice, 2 in-frame deletion, 1 missense, and 1 single-exon deletion. Reported ACMG classifications were 11 pathogenic, 7 likely pathogenic, and 2 VUS. Four causative changes were inherited and fourteen were de novo in the available summary. Appropriate Sequence Ontology classes include frameshift_variant, stop_gained, splice_donor_variant, splice_acceptor_variant, inframe_deletion, missense_variant, and exon_loss_variant. (glinton2021phenotypicexpansionof pages 3-4)

Variants are germline in the constitutional disorder. Somatic BPTF alterations studied in cancer should not be conflated with NEDDFL. Population frequencies were not available in the retrieved evidence; pathogenic loss-of-function variants are expected to be very rare, but every candidate requires direct gnomAD/ClinVar evaluation using its exact HGVS expression.

Functional consequence and epigenetics

The best-supported consequence is loss of function and haploinsufficiency. BPTF recognizes H3K4me3 through its PHD finger and H4K16ac through its bromodomain, helping recruit/position the NURF ATP-dependent remodeling machinery at chromatin. The disorder is therefore an epigenetic chromatin-remodeling disease, although no validated diagnostic DNA-methylation episignature was identified. (glinton2021phenotypicexpansionof pages 1-3)

No dominant-negative or gain-of-function disease mechanism, modifier gene, or reproducible human methylomic signature has been established. Large deletions involving 17q24.2 may produce broader contiguous-gene phenotypes and require CNV interpretation rather than automatic attribution solely to BPTF.

5. Environmental information

No toxin, radiation, pollution, occupational exposure, smoking, diet, alcohol, exercise pattern, or infectious agent is known to cause or trigger this Mendelian disorder. Lifestyle measures remain relevant to general health and management of secondary complications but are not primary prevention for a pathogenic germline BPTF variant. There is no zoonotic or transmissible component.

6. Mechanism and pathophysiology

Causal chain

The most defensible causal model is:

1. Upstream genetic lesion: heterozygous BPTF loss-of-function/deletion lowers functional BPTF dosage.
2. Chromatin-level defect: impaired NURF targeting/remodeling alters nucleosome positioning and transcriptional accessibility at developmentally regulated loci.
3. Neural-progenitor consequences: altered fate-determining transcription factors, prolonged progenitor cell cycle, and increased apoptosis reduce neuronal output.
4. Corticogenesis defect: impaired neuronal maturation and specification, reduced deep-layer neurons, and disrupted cortical lamination produce cortical hypoplasia.
5. Clinical manifestations: impaired cortical growth and circuit development plausibly generate microcephaly, developmental/intellectual disability, speech delay, motor impairment, and seizure susceptibility. (glinton2021phenotypicexpansionof pages 1-3, zapata2022generationofa pages 1-2)

In the 2022 mouse study, forebrain-specific Bptf loss produced “severe cortical hypoplasia”; prolonged progenitor cycling and high cell death reduced neuronal output, while lamination and acquisition of neuronal identities such as CTIP2-positive fates were impaired. RNA-seq showed dysregulation of fate-determining transcription factors and pathways involving neural development, apoptotic signaling, and amino-acid biosynthesis; dysregulated genes were enriched for MYC-binding sites, consistent with BPTF–MYC transcriptional cooperation. (zapata2022generationofa pages 1-2)

Suggested functional ontology

• GO:0006338 chromatin remodeling
• GO:0042393 histone binding
• GO:0006357 regulation of transcription by RNA polymerase II
• GO:0022008 neurogenesis
• GO:0007399 nervous system development
• GO:0006915 apoptotic process
• GO:0051301 cell division
• GO:0008652 cellular amino-acid biosynthetic process
• GO:0005634 nucleus
• GO:0000785 chromatin

Suggested cell annotations are neural progenitor cell, radial glial/neural stem cell, cortical projection neuron, deep-layer cortical neuron, and generic neuron (CL:0000540); subtype accessions should be checked against the current Cell Ontology release.

Molecular profiling and advanced technologies

Disease-relevant molecular profiling currently consists principally of mouse forebrain bulk RNA-seq. No robust human patient-brain transcriptome, proteome, metabolome, lipidome, single-cell atlas, spatial-transcriptomic dataset, organoid study, or clinical multi-omics signature was identified. The 2021 clinical authors noted the absence of a well-validated functional assay and suggested RNA-seq or proteomics might help resolve difficult variants, particularly missense variants; this remains investigational rather than standard diagnosis. (glinton2021phenotypicexpansionof pages 12-13)

There is no evidence that immune dysregulation, chronic inflammation, ischemia, fibrosis, mitochondrial failure, or a discrete metabolic block is a primary mechanism. Altered amino-acid-biosynthesis pathways in knockout mouse RNA-seq are downstream expression findings, not proof of a treatable human metabolic deficiency. (zapata2022generationofa pages 1-2)

7. Anatomical structures affected

The principal organ system is the central nervous system, especially the developing forebrain/cerebral cortex. Suggested anatomy terms include UBERON:0000955 brain, UBERON:0001890 cerebral cortex, and a current UBERON term for telencephalon/forebrain. Human imaging can be normal or show mild abnormalities, whereas complete forebrain-specific knockout in mice produces marked cortical hypoplasia. (zapata2022generationofa pages 1-2, glinton2021phenotypicexpansionof pages 4-5)

Secondary systems include craniofacial structures, distal limbs/skeleton, eyes, and general somatic growth. The relevant tissue is nervous tissue; implicated cells are neural progenitors and differentiating/mature cortical neurons. The main subcellular compartment is nuclear chromatin. Findings are not described as unilateral or lateralized.

8. Temporal development

The disorder is developmental, with congenital or early-childhood onset. Growth restriction or microcephaly may be present at birth, whereas some individuals develop postnatal microcephaly. Delayed milestones and language become evident in infancy or early childhood. (stankiewicz2017haploinsufficiencyofthe pages 1-2, glinton2021phenotypicexpansionof pages 4-5)

The course is chronic and lifelong rather than episodic or relapsing-remitting. Published ages extended from 23 months to 55 years in the expanded cohort, demonstrating adult survival. There is no validated staging system, progression rate, remission pattern, or defined end stage. Early childhood is likely the most important intervention window for speech, motor, educational, visual, and seizure services, but no study has quantified a critical therapeutic period. (glinton2021phenotypicexpansionof pages 3-4)

9. Inheritance and population

Inheritance is autosomal dominant. Most pathogenic variants arise de novo, although affected-parent transmission is established. When a parent carries the variant, the theoretical transmission probability is 50% per pregnancy; actual phenotype severity cannot be predicted reliably because expressivity is variable. For an apparently de novo variant, recurrence risk is low but not zero because parental germline mosaicism cannot be excluded by routine blood testing. (glinton2021phenotypicexpansionof pages 3-4)

Penetrance has not been quantified. Anticipation, founder effects, consanguinity effects, population-specific variants, and carrier frequency are not established. Both sexes are affected; one summary reported 14 males and 11 females, with no evidence for sex-linked inheritance. The published sample spans childhood through middle adulthood. (glinton2021phenotypicexpansionof pages 3-4)

No prevalence, incidence, geographic clustering, ancestry excess, or registry-derived epidemiologic estimate is available. It should be represented as an ultra-rare disorder of unknown prevalence rather than assigning a numerical rate.

10. Diagnostics

Recommended genomic approach

There are no formal NEDDFL diagnostic criteria. Diagnosis requires a compatible phenotype plus molecular confirmation.

1. First-line broad testing: trio exome sequencing or genome sequencing for unexplained syndromic developmental delay/intellectual disability, ideally with copy-number calling.
2. CNV testing: chromosomal microarray remains useful for exon/gene or larger 17q24.2 deletions and was used in foundational ascertainment. Genome sequencing may combine sequence and structural-variant detection.
3. Panel testing: a neurodevelopmental disorder/intellectual-disability or chromatinopathy panel should include BPTF and provide validated deletion/duplication analysis.
4. Single-gene testing: most appropriate when the phenotype is strongly suggestive or for familial segregation, prenatal diagnosis, and cascade testing.
5. Variant interpretation: apply ACMG/AMP criteria, parental testing, phenotype match, population frequency, predicted loss of function, transcript relevance, and CNV boundaries. A BPTF missense VUS alone does not establish diagnosis. (glinton2021phenotypicexpansionof pages 12-13, stankiewicz2017haploinsufficiencyofthe pages 1-2)

Karyotyping and FISH have low sensitivity for small sequence variants and are reserved for suspected large rearrangements or confirmation. Mitochondrial DNA and repeat-expansion testing are not disease-specific tests. RNA sequencing may help establish splice effects; proteomics and epigenomics remain investigational. (glinton2021phenotypicexpansionof pages 12-13)

Clinical evaluation after diagnosis

Recommended baseline assessment, extrapolated from the observed spectrum, includes detailed developmental/neuropsychological and speech-language evaluation; serial height, weight, and head circumference; neurologic examination; EEG for suspected seizures; brain MRI when neurologically indicated; ophthalmology; hearing assessment; musculoskeletal examination for scoliosis and limb anomalies; and review of feeding/nutrition. These are pragmatic surveillance recommendations, not evidence-based NEDDFL guidelines.

There is no blood, urine, enzyme, biopsy, metabolite, protein, or circulating biomarker diagnostic for the syndrome.

Differential diagnosis

Consider other chromatin-remodeling/chromatin-reader disorders, syndromic intellectual disability with microcephaly, copy-number syndromes involving 17q24, and growth disorders. Phenotypic overlap can include Silver–Russell syndrome: a cited adult with BPTF disruption was initially given that diagnosis. Distinction depends on genomic testing rather than facial gestalt alone. (glinton2021phenotypicexpansionof pages 13-13)

No newborn population screening or general-population carrier screening is available. Cascade testing is appropriate once a familial pathogenic variant is established.

11. Outcome and prognosis

No survival curve, disease-specific mortality rate, or life-expectancy estimate exists. Survival into adulthood—including an individual aged 55 years—has been documented, but the literature is too small to conclude that life expectancy is normal. (glinton2021phenotypicexpansionof pages 3-4)

Long-term morbidity is primarily neurodevelopmental and functional: communication limitations, intellectual disability, motor delay/hypotonia, epilepsy in a subset, growth impairment, ocular complications, and orthopedic issues. Recovery to a premorbid state is not expected because the condition reflects altered development; nevertheless, function can improve with therapy, education, communication supports, and control of secondary complications. No validated prognostic biomarker or genotype-based outcome calculator exists.

12. Treatment and real-world implementation

There is no approved disease-modifying, gene, RNA, cell, epigenetic, or targeted therapy for BPTF-related neurodevelopmental disorder. Management is individualized and multidisciplinary:

• early developmental intervention and special education;
• speech-language therapy, including augmentative and alternative communication where needed;
• physical and occupational therapy for hypotonia, motor delay, mobility, and adaptive skills;
• standard antiseizure treatment guided by seizure type and EEG;
• ophthalmologic correction/treatment;
• nutritional and feeding support;
• orthopedic surveillance and treatment for scoliosis or limb-related functional problems;
• psychosocial and family support.

Suggested NCIT concepts include Genetic Counseling, Supportive Care, Speech Therapy, Physical Therapy, Occupational Therapy, Anticonvulsant Therapy, and Vagus Nerve Stimulation; current NCIT identifiers should be validated during ingestion.

Case-level antiseizure implementations in the 2021 cohort included sodium valproate, levetiracetam, and a vagal nerve stimulator. These observations show real-world use but do not establish comparative efficacy or syndrome-specific response rates. (glinton2021phenotypicexpansionof pages 4-5)

A 2023 publication, Wu and Chen, “The effect of growth hormone treatment in children with novel BPTF gene variants: a report of two cases and literature review,” Molecular Genetics & Genomic Medicine, DOI 10.1002/mgg3.2066, was identified. Because direct outcome data were unavailable in the retrieved evidence, growth hormone should not be portrayed as established NEDDFL therapy; its use would require conventional endocrinologic evaluation and individualized risk–benefit review.

A 2024 epilepsy-focused report, Ferretti et al., “Epilepsy as a novel phenotype of BPTF-related disorders,” Pediatric Neurology, DOI 10.1016/j.pediatrneurol.2024.06.001, indicates growing characterization of seizure phenotypes, but detailed statistics could not be verified here.

No BPTF/NEDDFL-specific interventional ClinicalTrials.gov study or treatment algorithm was identified. Pharmacogenomic guidance specific to BPTF is absent.

13. Prevention

There is no lifestyle, medication, vaccine, or environmental intervention that prevents a de novo pathogenic BPTF variant. Primary prevention is therefore limited to informed reproductive options when a familial variant is known: genetic counseling, prenatal diagnosis, and preimplantation genetic testing for monogenic disease. Secondary prevention consists of early molecular diagnosis and prompt developmental, communication, vision, nutritional, orthopedic, and epilepsy evaluation. Tertiary prevention aims to reduce complications and maximize function through ongoing multidisciplinary care.

For confirmed de novo cases, parental testing informs recurrence counseling but cannot eliminate residual germline-mosaicism risk. For inherited variants, cascade testing can identify relatives who may benefit from clinical evaluation and reproductive counseling. (glinton2021phenotypicexpansionof pages 3-4)

14. Other species and natural disease

No naturally occurring BPTF-associated veterinary disease, affected breed, zoonotic potential, or cross-species transmission was identified. Orthologous developmental function is conserved experimentally in vertebrates. Relevant taxa are Danio rerio (NCBI Taxonomy 7955) and Mus musculus (NCBI Taxonomy 10090). Species-specific Bptf gene identifiers should be obtained directly from the current NCBI Gene/Alliance records before database ingestion.

15. Model organisms

Zebrafish

CRISPR-Cas9 disruption of bptf in F0 zebrafish caused reduced head size, increased TUNEL-positive apoptosis, altered phospho-histone-H3 proliferation measures, and abnormal craniofacial patterning, including increased ceratohyal angle. This recapitulates the human microcephaly/craniofacial axis and supports a developmental loss-of-function mechanism. Limitations include F0 mosaicism, uncertain allele dosage, and incomplete modeling of cognition and speech. (stankiewicz2017haploinsufficiencyofthe pages 1-2)

Mouse

The 2022 Emx1-Cre forebrain-specific Bptf conditional knockout survived into adulthood but was smaller and had severe cortical hypoplasia, prolonged progenitor cycling, increased cell death, reduced neuronal output, disturbed lamination, fewer deep-layer neurons, and impaired neuronal maturation. It is a strong mechanistic model for corticogenesis and transcriptomic studies. Its major limitation is that biallelic tissue-specific ablation is more severe and spatially restricted than constitutional human heterozygous haploinsufficiency; heterozygous mice reportedly had much smaller effects. (glinton2021phenotypicexpansionof pages 1-3, zapata2022generationofa pages 1-2)

No validated patient-derived iPSC, brain-organoid, rat, Drosophila, C. elegans, or naturally occurring animal model was identified in the retrieved disease-specific evidence.

Recent research and authoritative interpretation

The field’s current interpretation is that BPTF-related NDD belongs to the broader class of dosage-sensitive chromatinopathies. Human genetics strongly supports haploinsufficiency, while zebrafish and mouse experiments connect the genetic lesion to apoptosis, progenitor dysfunction, reduced neuronal production, and impaired cortical fate specification. The major unresolved translational challenge is that the severe knockout models do not precisely reproduce the variable heterozygous human phenotype. Human cellular models and variant-sensitive functional assays are priorities, particularly for missense and inherited variants. (zapata2022generationofa pages 1-2, glinton2021phenotypicexpansionof pages 12-13)

The most important recent developments are therefore phenotypic rather than therapeutic: recognition of inherited disease and milder expression, expanded seizure and ophthalmologic phenotypes, exploratory growth-hormone treatment, and mechanistic forebrain RNA-seq. No precision therapy has reached clinical implementation.

Key primary sources and abstract quotations

1. Stankiewicz et al. “Haploinsufficiency of the Chromatin Remodeler BPTF Causes Syndromic Developmental and Speech Delay, Postnatal Microcephaly, and Dysmorphic Features.” American Journal of Human Genetics 101:503–515. Published October 2017. DOI: 10.1016/j.ajhg.2017.08.014. Landmark human cohort plus zebrafish validation: ten unrelated individuals, 8 loss-of-function and 2 missense variants, with DD/ID and speech delay in 10/10. (stankiewicz2017haploinsufficiencyofthe pages 1-2)

2. Glinton et al. “Phenotypic expansion of the BPTF-related neurodevelopmental disorder with dysmorphic facies and distal limb anomalies.” American Journal of Medical Genetics Part A 185:1366–1378. Published January 2021. DOI: 10.1002/ajmg.a.62102. Abstract quotation: “To expand the NEDDFL phenotypic spectrum, we describe the clinical features in 25 novel individuals with 20 distinct, clinically relevant variants in BPTF, including four individuals with inherited changes in BPTF.” It further reports “mild brain abnormalities, seizures, scoliosis, and a variety of ophthalmologic complications.” (glinton2021phenotypicexpansionof pages 1-3)

3. Zapata, Yan, and Picketts. “Generation of a mouse model of the neurodevelopmental disorder with dysmorphic facies and distal limb anomalies (NEDDFL) syndrome.” Human Molecular Genetics 31:3405–3421. Published May 2022. DOI: 10.1093/hmg/ddac119. Abstract quotation: “Prolonged progenitor cell cycle length and a high incidence of cell death reduced neuronal output.” The authors also report disrupted cortical lamination, neuronal maturation defects, and RNA-seq pathway changes. (zapata2022generationofa pages 1-2)

Knowledge-base-ready summary

The following artifact consolidates evidence-supported disease, phenotype, mechanism, diagnostic, treatment, anatomy, and model annotations, while explicitly marking unverified identifiers and unknown fields.

Table: This table summarizes knowledge-base-ready findings for BPTF-related neurodevelopmental disorder/NEDDFL, including core phenotypes, mechanism, diagnostics, inheritance, and model evidence. It also flags important unknowns and limitations where the available evidence is sparse or unverified.

Critical data gaps

The following should remain explicitly unknown/not established in a production knowledge base: disease-specific MONDO and Orphanet identifiers unless separately verified; prevalence and incidence; penetrance; ancestry or geographic effects; founder variants; quantitative quality of life; standardized diagnostic criteria; longitudinal natural history; life expectancy; prognostic biomarkers; validated episignature; human single-cell/spatial/multi-omics profiles; treatment response rates; and disease-modifying or preventive therapy. Apparent precision beyond the small published cohorts would be misleading.

References

1. (glinton2021phenotypicexpansionof pages 1-3): Kevin E. Glinton, Anna C. E. Hurst, Kevin M. Bowling, Ingrid Cristian, Devon Haynes, Dusit Adstamongkonkul, Oskar Schnappauf, David B. Beck, Carole Brewer, Aditi Shah Parikh, Deepali N. Shinde, Alan Donaldson, Ariel Brautbar, Saskia Koene, Arie van Haeringen, Amélie Piton, Yline Capri, Margherita Furlan, Elena Gardella, Rikke Steensbjerre Møller, Irma van de Beek, Linda Zuurbier, Phillis Lakeman, Allan Bayat, Julian Martinez, Rebecca Signer, Pernille M. Torring, Morten Buch Engelund, Karen W. Gripp, Louise Amlie‐Wolf, Lindsay B. Henderson, Alina T. Midro, Eugeniusz Tarasów, Beata Stasiewicz‐Jarocka, Diana Moskal‐Jasinska, Paul Vos, Felix Boschann, Corinna Stoltenburg, Oliver Puk, Inger‐Lise Mero, Kristine Lossius, Cyril Mignot, Boris Keren, Johanna C. Acosta Guio, Ignacio Briceño, Alberto Gomez, Yaping Yang, and Pawel Stankiewicz. Phenotypic expansion of the bptf‐related neurodevelopmental disorder with dysmorphic facies and distal limb anomalies. American Journal of Medical Genetics. Part a, 185:1366-1378, Jan 2021. URL: https://doi.org/10.1002/ajmg.a.62102, doi:10.1002/ajmg.a.62102. This article has 33 citations and is from a peer-reviewed journal.

2. (stankiewicz2017haploinsufficiencyofthe pages 1-2): Paweł Stankiewicz, Tahir N. Khan, Przemyslaw Szafranski, Leah Slattery, Haley Streff, Francesco Vetrini, Jonathan A. Bernstein, Chester W. Brown, Jill A. Rosenfeld, Surya Rednam, Sarah Scollon, Katie L. Bergstrom, Donald W. Parsons, Sharon E. Plon, Marta W. Vieira, Caio R.D.C. Quaio, Wagner A.R. Baratela, Johanna C. Acosta Guio, Ruth Armstrong, Sarju G. Mehta, Patrick Rump, Rolph Pfundt, Raymond Lewandowski, Erica M. Fernandes, Deepali N. Shinde, Sha Tang, Juliane Hoyer, Christiane Zweier, André Reis, Carlos A. Bacino, Rui Xiao, Amy M. Breman, Janice L. Smith, Nicholas Katsanis, Bret Bostwick, Bernt Popp, Erica E. Davis, and Yaping Yang. Haploinsufficiency of the chromatin remodeler bptf causes syndromic developmental and speech delay, postnatal microcephaly, and dysmorphic features. American journal of human genetics, 101 4:503-515, Oct 2017. URL: https://doi.org/10.1016/j.ajhg.2017.08.014, doi:10.1016/j.ajhg.2017.08.014. This article has 113 citations and is from a highest quality peer-reviewed journal.

3. (glinton2021phenotypicexpansionof pages 3-4): Kevin E. Glinton, Anna C. E. Hurst, Kevin M. Bowling, Ingrid Cristian, Devon Haynes, Dusit Adstamongkonkul, Oskar Schnappauf, David B. Beck, Carole Brewer, Aditi Shah Parikh, Deepali N. Shinde, Alan Donaldson, Ariel Brautbar, Saskia Koene, Arie van Haeringen, Amélie Piton, Yline Capri, Margherita Furlan, Elena Gardella, Rikke Steensbjerre Møller, Irma van de Beek, Linda Zuurbier, Phillis Lakeman, Allan Bayat, Julian Martinez, Rebecca Signer, Pernille M. Torring, Morten Buch Engelund, Karen W. Gripp, Louise Amlie‐Wolf, Lindsay B. Henderson, Alina T. Midro, Eugeniusz Tarasów, Beata Stasiewicz‐Jarocka, Diana Moskal‐Jasinska, Paul Vos, Felix Boschann, Corinna Stoltenburg, Oliver Puk, Inger‐Lise Mero, Kristine Lossius, Cyril Mignot, Boris Keren, Johanna C. Acosta Guio, Ignacio Briceño, Alberto Gomez, Yaping Yang, and Pawel Stankiewicz. Phenotypic expansion of the bptf‐related neurodevelopmental disorder with dysmorphic facies and distal limb anomalies. American Journal of Medical Genetics. Part a, 185:1366-1378, Jan 2021. URL: https://doi.org/10.1002/ajmg.a.62102, doi:10.1002/ajmg.a.62102. This article has 33 citations and is from a peer-reviewed journal.

4. (zapata2022generationofa pages 1-2): Gerardo Zapata, Keqin Yan, and David J Picketts. Generation of a mouse model of the neurodevelopmental disorder with dysmorphic facies and distal limb anomalies (neddfl) syndrome. Human molecular genetics, 31:3405-3421, May 2022. URL: https://doi.org/10.1093/hmg/ddac119, doi:10.1093/hmg/ddac119. This article has 14 citations and is from a domain leading peer-reviewed journal.

5. (glinton2021phenotypicexpansionof pages 12-13): Kevin E. Glinton, Anna C. E. Hurst, Kevin M. Bowling, Ingrid Cristian, Devon Haynes, Dusit Adstamongkonkul, Oskar Schnappauf, David B. Beck, Carole Brewer, Aditi Shah Parikh, Deepali N. Shinde, Alan Donaldson, Ariel Brautbar, Saskia Koene, Arie van Haeringen, Amélie Piton, Yline Capri, Margherita Furlan, Elena Gardella, Rikke Steensbjerre Møller, Irma van de Beek, Linda Zuurbier, Phillis Lakeman, Allan Bayat, Julian Martinez, Rebecca Signer, Pernille M. Torring, Morten Buch Engelund, Karen W. Gripp, Louise Amlie‐Wolf, Lindsay B. Henderson, Alina T. Midro, Eugeniusz Tarasów, Beata Stasiewicz‐Jarocka, Diana Moskal‐Jasinska, Paul Vos, Felix Boschann, Corinna Stoltenburg, Oliver Puk, Inger‐Lise Mero, Kristine Lossius, Cyril Mignot, Boris Keren, Johanna C. Acosta Guio, Ignacio Briceño, Alberto Gomez, Yaping Yang, and Pawel Stankiewicz. Phenotypic expansion of the bptf‐related neurodevelopmental disorder with dysmorphic facies and distal limb anomalies. American Journal of Medical Genetics. Part a, 185:1366-1378, Jan 2021. URL: https://doi.org/10.1002/ajmg.a.62102, doi:10.1002/ajmg.a.62102. This article has 33 citations and is from a peer-reviewed journal.

6. (glinton2021phenotypicexpansionof pages 4-5): Kevin E. Glinton, Anna C. E. Hurst, Kevin M. Bowling, Ingrid Cristian, Devon Haynes, Dusit Adstamongkonkul, Oskar Schnappauf, David B. Beck, Carole Brewer, Aditi Shah Parikh, Deepali N. Shinde, Alan Donaldson, Ariel Brautbar, Saskia Koene, Arie van Haeringen, Amélie Piton, Yline Capri, Margherita Furlan, Elena Gardella, Rikke Steensbjerre Møller, Irma van de Beek, Linda Zuurbier, Phillis Lakeman, Allan Bayat, Julian Martinez, Rebecca Signer, Pernille M. Torring, Morten Buch Engelund, Karen W. Gripp, Louise Amlie‐Wolf, Lindsay B. Henderson, Alina T. Midro, Eugeniusz Tarasów, Beata Stasiewicz‐Jarocka, Diana Moskal‐Jasinska, Paul Vos, Felix Boschann, Corinna Stoltenburg, Oliver Puk, Inger‐Lise Mero, Kristine Lossius, Cyril Mignot, Boris Keren, Johanna C. Acosta Guio, Ignacio Briceño, Alberto Gomez, Yaping Yang, and Pawel Stankiewicz. Phenotypic expansion of the bptf‐related neurodevelopmental disorder with dysmorphic facies and distal limb anomalies. American Journal of Medical Genetics. Part a, 185:1366-1378, Jan 2021. URL: https://doi.org/10.1002/ajmg.a.62102, doi:10.1002/ajmg.a.62102. This article has 33 citations and is from a peer-reviewed journal.

7. (glinton2021phenotypicexpansionof pages 9-10): Kevin E. Glinton, Anna C. E. Hurst, Kevin M. Bowling, Ingrid Cristian, Devon Haynes, Dusit Adstamongkonkul, Oskar Schnappauf, David B. Beck, Carole Brewer, Aditi Shah Parikh, Deepali N. Shinde, Alan Donaldson, Ariel Brautbar, Saskia Koene, Arie van Haeringen, Amélie Piton, Yline Capri, Margherita Furlan, Elena Gardella, Rikke Steensbjerre Møller, Irma van de Beek, Linda Zuurbier, Phillis Lakeman, Allan Bayat, Julian Martinez, Rebecca Signer, Pernille M. Torring, Morten Buch Engelund, Karen W. Gripp, Louise Amlie‐Wolf, Lindsay B. Henderson, Alina T. Midro, Eugeniusz Tarasów, Beata Stasiewicz‐Jarocka, Diana Moskal‐Jasinska, Paul Vos, Felix Boschann, Corinna Stoltenburg, Oliver Puk, Inger‐Lise Mero, Kristine Lossius, Cyril Mignot, Boris Keren, Johanna C. Acosta Guio, Ignacio Briceño, Alberto Gomez, Yaping Yang, and Pawel Stankiewicz. Phenotypic expansion of the bptf‐related neurodevelopmental disorder with dysmorphic facies and distal limb anomalies. American Journal of Medical Genetics. Part a, 185:1366-1378, Jan 2021. URL: https://doi.org/10.1002/ajmg.a.62102, doi:10.1002/ajmg.a.62102. This article has 33 citations and is from a peer-reviewed journal.

8. (glinton2021phenotypicexpansionof pages 13-13): Kevin E. Glinton, Anna C. E. Hurst, Kevin M. Bowling, Ingrid Cristian, Devon Haynes, Dusit Adstamongkonkul, Oskar Schnappauf, David B. Beck, Carole Brewer, Aditi Shah Parikh, Deepali N. Shinde, Alan Donaldson, Ariel Brautbar, Saskia Koene, Arie van Haeringen, Amélie Piton, Yline Capri, Margherita Furlan, Elena Gardella, Rikke Steensbjerre Møller, Irma van de Beek, Linda Zuurbier, Phillis Lakeman, Allan Bayat, Julian Martinez, Rebecca Signer, Pernille M. Torring, Morten Buch Engelund, Karen W. Gripp, Louise Amlie‐Wolf, Lindsay B. Henderson, Alina T. Midro, Eugeniusz Tarasów, Beata Stasiewicz‐Jarocka, Diana Moskal‐Jasinska, Paul Vos, Felix Boschann, Corinna Stoltenburg, Oliver Puk, Inger‐Lise Mero, Kristine Lossius, Cyril Mignot, Boris Keren, Johanna C. Acosta Guio, Ignacio Briceño, Alberto Gomez, Yaping Yang, and Pawel Stankiewicz. Phenotypic expansion of the bptf‐related neurodevelopmental disorder with dysmorphic facies and distal limb anomalies. American Journal of Medical Genetics. Part a, 185:1366-1378, Jan 2021. URL: https://doi.org/10.1002/ajmg.a.62102, doi:10.1002/ajmg.a.62102. This article has 33 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.